Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche and Sysmex Expand 25-Year Partnership to Foster More Sustainable Diagnostic Solutions

By LabMedica International staff writers
Posted on 04 Aug 2023

Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan) have expanded their Global Business Partnership Agreement. More...

The renewed agreement reinforces the commitment of both companies to their long-established collaboration. Under the revised terms, Roche, which has been collaborating with Sysmex for 25 years, will continue to offer Sysmex's hematology products, complementing its comprehensive laboratory solutions portfolio. The Global Business Partnership Agreement between Roche and Sysmex promises to assist patients requiring diagnostic solutions and aims to enhance the efficiency and effectiveness of lab testing by offering integrated in-vitro diagnostics (IVD) technologies through a single provider.

The commercial and R&D collaboration between Roche and Sysmex was initiated in 1998, and the companies have since consistently strengthened their partnership. In 2020, both companies signed the Global Business Partnership Agreement to broaden their partnership further and enhance the customer experience. As of 2023, with updated terms and an expanded scope, both companies have reaffirmed their long-standing partnership and commitment to fostering a more sustainable future for society. The revised non-exclusive agreement ushers in a new dimension of cooperation, incorporating an additional eco-social agreement to jointly investigate more sustainable diagnostic solutions. By extending their long-standing collaboration beyond the current portfolio, both companies have demonstrated their commitment to seeking more sustainable solutions.

“We are delighted to expand our 25-year partnership with Sysmex in the area of hematology and in exploring more sustainable diagnostics solutions,” said Matt Sause, CEO of Roche Diagnostics. “Roche and Sysmex both have a long-standing history of delivering reliable and innovative solutions for patients and I am very happy to see this collaboration grow.”

“We are pleased to announce the renewal of our partnership with Roche, reaffirming our commitment to long-term collaboration,” added Kaoru Asano, President of Sysmex Corporation. “Developing our partnerships in the field of diagnostics even further and addressing enduring eco-social challenges represents a significant milestone in advancing our alliance to the next level. Together, we firmly believe in making even greater contributions to our customers in laboratories and creating a sustainable society."

Related Links:
Roche
Sysmex Corporation


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.